Therapeutic drug monitoring.

The value of therapeutic drug monitoring to the practising physician--an hypothesis in need of testing. Br J Clin Pharmacol (1989) 1.55

An intelligent and cost-effective computer dosing system for individualizing FK506 therapy in transplantation and autoimmune disorders. J Clin Pharmacol (1993) 1.09

The value of therapeutic drug monitoring to the practising physician--an hypothesis needing sensible application. Br J Clin Pharmacol (1989) 1.06

Best practice in therapeutic drug monitoring. Br J Clin Pharmacol (1998) 1.04

Overview of therapeutic drug monitoring. Korean J Intern Med (2009) 0.94

Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response. Therap Adv Gastroenterol (2013) 0.92

Therapeutic drug monitoring of immunosuppressant drugs. Br J Clin Pharmacol (1999) 0.83

Antimicrobial therapy in neonates, infants and children. Clin Pharmacokinet (1989) 0.83

A review on therapeutic drug monitoring of immunosuppressant drugs. Iran J Basic Med Sci (2011) 0.83

Incidence of digoxin toxicity in outpatients. West J Med (1994) 0.82

Antiretroviral therapeutic drug monitoring in Canada: current status and recommendations for clinical practice. Can J Hosp Pharm (2009) 0.79

The value of therapeutic drug monitoring. Br J Clin Pharmacol (1990) 0.75

Incorporating pharmacodynamic considerations into caffeine therapeutic drug monitoring in preterm neonates. BMC Pharmacol Toxicol (2016) 0.75

Pediatric Lisfranc injury: "bunk bed" fracture. AJR Am J Roentgenol (1981) 3.13

Genetic control of drug levels in man: antipyrine. Science (1968) 3.03

Genetic control of drug levels in man: phenylbutazone. Science (1968) 2.72

The antipyrine test in clinical pharmacology: conceptions and misconceptions. Clin Pharmacol Ther (1979) 2.54

Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man. J Clin Invest (1969) 2.47

Genetic control of dicumarol levels in man. J Clin Invest (1968) 2.45

Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care (2001) 1.94

Robin sequence and oligodactyly in mother and son. Am J Med Genet (1986) 1.82

Enhancement of theophylline clearance by oral activated charcoal. Clin Pharmacol Ther (1983) 1.76

Reduced warfarin binding of albumin variants. Science (1977) 1.73

Gas-chromatographic determination of 5-fluorocytosine in human serum. Clin Chem (1976) 1.67

Studies on the disposition of antipyrine, aminopyrine, and phenacetin using plasma, saliva, and urine. Clin Pharmacol Ther (1975) 1.65

Quantitative assessment of hepatic function by breath analysis after oral administration of (14C)aminopyrine. Ann Intern Med (1975) 1.57

Comparison of plasma levels of antipyrine, tolbutamide, and warfarin after oral and intravenous administration. Clin Pharmacol Ther (1974) 1.56

Genetic and environmental factors affecting drug response in man. Fed Proc (1972) 1.50

Disposition of nicotine and eight metabolites in smokers and nonsmokers: identification in smokers of two metabolites that are longer lived than cotinine. Clin Pharmacol Ther (1990) 1.49

Assessment of aminopyrine metabolism in man by breath analysis after oral administration of 14C-aminopyrine. Effects of phenobarbital, disulfiram and portal cirrhosis. N Engl J Med (1974) 1.47

Impairment of drug metabolism in man by allopurinol and nortriptyline. N Engl J Med (1970) 1.44

Smoking-induced changes in nicotine disposition: application of a new HPLC assay for nicotine and its metabolites. Clin Pharmacol Ther (1982) 1.44

Failure of indomethacin and warfarin to interact in normal human volunteers. J Clin Pharmacol (1975) 1.43

Genetic and environmental factors affecting ethanol metabolism in man. Clin Pharmacol Ther (1971) 1.41

Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia (1999) 1.40

Feline hyperthyroidism: pretreatment clinical and laboratory evaluation of 131 cases. J Am Vet Med Assoc (1983) 1.38

Acrodysostosis. A syndrome of peripheral dysostosis, nasal hypoplasia, and mental retardation. Am J Dis Child (1971) 1.38

Genetic and environmental factors affecting drug disposition in man. Clin Pharmacol Ther (1977) 1.35

Genetic control of interindividual variations in the inducibility of aryl hydrocarbon hydroxylase in cultured human lymphocytes. Cancer Res (1976) 1.34

Effects of etiocholanolone-induced fever on plasma antipyrine half-lives and metabolic clearance. Clin Pharmacol Ther (1975) 1.32

Distichiasis-lymphedema. A hereditary syndrome of multiple congenital defects. Am J Dis Child (1970) 1.30

Further observations on relationships between antipyrine half-life, clearance and volume of distribution: an appraisal of alternative kinetic parameters used to assess the elimination of antipyrine. Clin Pharmacokinet (1980) 1.19

Use of hemoperfusion for treatment of theophylline intoxication. Am J Med (1983) 1.16

Acceleration of the body clearance of phenobarbital by oral activated charcoal. N Engl J Med (1982) 1.15

Expanded role of charcoal therapy in the poisoned and overdosed patient. Arch Intern Med (1986) 1.15

Antipyrine metabolism during the menstrual cycle. Clin Pharmacol Ther (1980) 1.15

Therapeutic lessons from pharmacogenetics. Ann Intern Med (1997) 1.13

Genetic control of isozyme patterns in human tissues. Prog Med Genet (1965) 1.13

Disposition of aminopyrine, antipyrine, diazepam, and indocyanine green in patients with liver disease or on anticonvulsant drug therapy: diazepam breath test and correlations in drug elimination. J Lab Clin Med (1977) 1.13

Lactate dehydrogenase isozymes: kinetic properties at high enzyme concentrations. Science (1970) 1.12

Genetic variation as a guide to drug development. Science (1998) 1.12

Inhibition of theophylline metabolism by long-term allopurinol administration. Clin Pharmacol Ther (1981) 1.12

Canine hepatocellular carcinoma. Vet Pathol (1981) 1.10

Temporal variations of antipyrine half-life in man. Clin Pharmacol Ther (1977) 1.10

Lactate and pyruvate concentrations in exercised ischemic canine muscle: relationship of tissue substrate level to lactate dehydrogenase isozyme pattern. Proc Natl Acad Sci U S A (1966) 1.10

Assessment of methods to identify sources of interindividual pharmacokinetic variations. Clin Pharmacokinet (1983) 1.09

Model for theophylline overdose treatment with oral activated charcoal. Clin Pharmacol Ther (1984) 1.09

Altered plasma half-lives of antipyrine, propylthiouracil, and methimazole in thyroid dysfunction. Clin Pharmacol Ther (1975) 1.07

Pharmacokinetic interpretation of data gathered during therapeutic drug monitoring. Clin Chem (1976) 1.07

Temporal variations in acetaminophen and phenacetin half-life in man. Clin Pharmacol Ther (1975) 1.05

Therapeutic monitoring of anticonvulsant drugs: gas-chromatographic simultaneous determination of primidone, phenylethylmalonamide, carbamazepine, and diphenylhydantoin. Clin Chem (1975) 1.04

Radioimmunoassay of plasma nicotine in habituated and naive smokers. Clin Pharmacol Ther (1974) 1.04

Quinine-induced alterations in drug disposition. Clin Pharmacol Ther (1975) 1.03

Induction of drug-metabolizing enzymes in liver microsomes of mice and rats by softwood bedding. Science (1967) 1.01

Diurnal rhythms of aminopyrine metabolism: failure to sleep deprivation to affect them. Clin Pharmacol Ther (1978) 1.01

Concentration-dependent effects of fatty acids on warfarin binding to albumin. Biochem Pharmacol (1977) 1.01

Polygenic factors controlling drug response. Med Clin North Am (1974) 1.00

Genetic variation in rates of antipyrine metabolite formation: a study in uninduced twins. Proc Natl Acad Sci U S A (1981) 0.98

Hepatic drug metabolism in ten strains of Norway rat before and after pretreatment with phenobarbital. Proc Soc Exp Biol Med (1969) 0.98

The roles of synthesis and degradation in determining tissue concentrations of lactate dehydrogenase-5. Proc Natl Acad Sci U S A (1969) 0.98

Relationship between plasma antipyrine half-lives and hepatic microsomal drug metabolism in dogs. Pharmacology (1973) 0.97

Inhibition of drug metabolism by levodopa in combination with a dopa-decarboxylase inhibitor. Lancet (1971) 0.96

The intrauterine probe electrode. Am J Obstet Gynecol (1991) 0.96

Effects of metabolites of primaquine and acetanilid on normal and glucose-6-phosphate dehydrogenase-deficient erythrocytes. J Pharmacol Exp Ther (1968) 0.96

Aglossia-adactylia. Radiology (1978) 0.96

Hepatic lysosomal copper protein in dogs with an inherited copper toxicosis. Hepatology (1981) 0.96

Comparative study of methods for quantitation of lactate dehydrogenase isozymes. Anal Biochem (1970) 0.96

Factors altering the responsiveness of mice to hexobarbital. Pharmacology (1968) 0.95

Protection of lactate dehydrogenase isozymes from heat inactivation and enzymatic degradation. Ann N Y Acad Sci (1968) 0.95

Lack of effect of oral activated charcoal on imipramine clearance. Clin Pharmacol Ther (1985) 0.94

Unaltered metabolism of antipyrine and tolbutamide in fasting man. Clin Pharmacol Ther (1975) 0.94

Discordance in monozygotic twins for aglossia-adactylia, and possible clues to the pathogenesis of the syndrome. Birth Defects Orig Artic Ser (1978) 0.93

Aicardi syndrome, papilloma of the choroid plexus, cleft lip, and cleft of the posterior palate. J Pediatr (1984) 0.93

Feline intestinal adenocarcinoma. A clinicopathologic study of 22 cases. Vet Pathol (1976) 0.93

Canine bile duct carcinoma. Vet Pathol (1981) 0.93

Evidence for post-transcriptional stabilization of ribosomal precursor ribonucleic acid by phenobarbital. Mol Pharmacol (1972) 0.93

Monogenic control of variations in antipyrine metabolite formation. New polymorphism of hepatic drug oxidation. J Clin Invest (1983) 0.93

The binding of sulfaphenazole to fetal, neonatal, and adult human plasma albumin. Clin Pharmacol Ther (1972) 0.93

Heterogeneity of N-and O-methyltransferases. Mol Pharmacol (1970) 0.92

Inhibition of drug metabolism in man. Drug Metab Dispos (1974) 0.92

Studies on theobromine disposition in normal subjects. Alterations induced by dietary abstention from or exposure to methylxanthines. Clin Pharmacol Ther (1978) 0.92

Metabolism of nicotine. Drug Metab Rev (1991) 0.92

Effects of size and frequency of oral doses of charcoal on theophylline clearance. Clin Pharmacol Ther (1983) 0.92

Underrepresentation of women in clinical drug trials. Clin Pharmacol Ther (1993) 0.92

Intrapericardial teratoma and bronchogenic cyst. Review of literature and report of successful surgery in infant with intrapericardial teratoma. J Thorac Cardiovasc Surg (1974) 0.92

Quantitative gas-chromatographic flame-ionization method for chloramphenicol in human serum. Clin Chem (1977) 0.92

Skeletal lesions following meningococcemia and disseminated intravascular coagulation. A recognizable skeletal dystrophy. Am J Dis Child (1983) 0.91

Interindividual and intraindividual variations in aryl hydrocarbon hydroxylase in monocytes from monozygotic and dizygotic twins. Cancer Res (1977) 0.91

Sexual dimorphism of nicotine metabolism and distribution in the rat. Studies in vivo and in vitro. Drug Metab Dispos (1989) 0.91

Indomethacin disposition and indomethacin-induced platelet dysfunction in premature infants. J Clin Pharmacol (1978) 0.91

Pharmacokinetics of dexamethasone and its relationship to dexamethasone suppression test outcome in depressed patients and healthy control subjects. Biol Psychiatry (1997) 0.91

Recent progress in pharmacogenetics. Adv Pharmacol Chemother (1969) 0.90

Inheritance of copper toxicosis in Bedlington terriers. Am J Vet Res (1980) 0.90

Measurement of erythrocyte glucose-6-phosphate dehydrogenase activity with a centrifugal analyzer. Clin Chem (1975) 0.90

Lactate dehydrogenase Isozymes: substrate inhibition in various human tissues. Science (1965) 0.90

Lactate dehydrogenase isozyme patterns of human platelets and bovine lens fibers. Science (1965) 0.90

Genetic and environmental factors affecting hexobarbital metabolism in mice. Ann N Y Acad Sci (1968) 0.90

Characterization of cytochrome P-450-dependent aminopyrine N-demethylase in rat brain: comparison with hepatic aminopyrine N-demethylation. J Pharmacol Exp Ther (1979) 0.90

Pharmacokinetics of nicotine and 12 metabolites in the rat. Application of a new radiometric high performance liquid chromatography assay. Drug Metab Dispos (1988) 0.89

Advances in pharmacogenetics. Prog Med Genet (1973) 0.89